Key Takeaways
- BioNTech (BNTX) has commenced a public exchange offer for all outstanding shares of CureVac (CVAC), valued at approximately $5.46 in BioNTech American Depositary Shares (ADSs) per CureVac share, aiming for 100% ownership by December 3, 2025.
- The European Union is set to approve its 19th package of sanctions against Russia, targeting two Chinese oil refineries, one Chinese trading firm, and an entity involved in circumvention, alongside a ban on Russian LNG imports by January 2027.
- AT&T (T), Boston Scientific (BSX), and GE Vernova (GEV) have reported strong Q3 2025 earnings, with all three companies exceeding analyst expectations for adjusted EPS and revenue, and some raising full-year guidance.
- China has overtaken the U.S. as Germany's top trading partner in the first eight months of 2025, driven by surging Chinese imports and a decline in German exports to the U.S. due to higher tariffs.
- Volkswagen (VOW) cannot rule out short-term production impacts due to ongoing issues with chip supplier Nexperia, which is embroiled in a dispute between the Dutch and Chinese governments.
Corporate Earnings Highlight Q3 Strength
Several major companies have released their third-quarter 2025 earnings, largely surpassing market expectations. AT&T (T) reported adjusted earnings per share (EPS) of $0.54, matching estimates, on revenues of $30.7 billion, slightly below the estimated $30.86 billion. The telecommunications giant saw robust growth in its wireless postpaid phone net adds, reaching 405,000, significantly exceeding the estimated 338,550. Adjusted EBITDA came in at $11.9 billion, above the $11.77 billion estimate.
Boston Scientific (BSX) delivered a strong performance, with adjusted EPS of $0.75, beating the $0.71 estimate, and revenue of $5.07 billion, surpassing the $4.97 billion consensus. The medical device company also raised its full-year 2025 adjusted EPS outlook to $3.02 to $3.04, up from the previous $2.95 to $2.99 range, and projected Q4 adjusted EPS of $0.77 to $0.79.
GE Vernova (GEV) also reported impressive Q3 2025 results, with EPS of $1.64, slightly above the $1.62 estimate, and revenue of $9.83 billion, significantly exceeding the $9.17 billion estimate. The company reaffirmed its 2025 guidance, expecting revenue to trend towards the higher end of its $36-$37 billion range.
BioNTech Launches Exchange Offer for CureVac
BioNTech SE (BNTX) has initiated a public exchange offer to acquire all outstanding shares of CureVac N.V. (CVAC). Under the terms of the purchase agreement, each CureVac share will be exchanged for approximately $5.46 in BioNTech American Depositary Shares (ADSs). The offer is subject to a collar mechanism, where the exchange ratio will be 0.04318 BioNTech ADSs if BioNTech's 10-day volume-weighted average price (VWAP) is greater than or equal to $126.55, and 0.06476 if the VWAP is less than or equal to $84.37. The offer is contingent on at least 80% of CureVac's shares being tendered and is set to expire at 9:00 A.M. New York City time on December 3, 2025. This strategic move aims to effectuate a corporate reorganization, resulting in BioNTech owning 100% of CureVac's business.
EU Broadens Sanctions Against Russia, Targeting Chinese Firms
The European Union is preparing to implement its 19th package of sanctions against Russia, with EU diplomats indicating the measures will include penalties against two Chinese oil refineries, one Chinese trading firm, and an entity involved in circumvention activities. The sanctions package also targets four companies within China's oil industry. These new restrictions are part of a broader effort to tighten pressure on Moscow's energy and financial sectors, including a ban on imports of Russian liquefied natural gas (LNG) starting January 1, 2027, a year earlier than previously planned. Additionally, the package will impose a full transaction ban on major Russian energy companies like Rosneft and Gazpromneft.
Meanwhile, Russia's Deputy Prime Minister Alexander Novak's office reported that Russian oil companies are increasing their diesel and gasoline output.
Global Trade Shifts: China Becomes Germany's Top Partner
In a significant shift in global trade dynamics, China has surpassed the United States to become Germany's top trading partner in the first eight months of 2025. Preliminary data from the German statistics office shows that German imports and exports with China totaled 163.4 billion euros ($190.7 billion) from January to August, narrowly exceeding trade with the U.S., which stood at 162.8 billion euros. This change comes as higher U.S. tariffs have weighed on German exports to the United States, which fell 7.4% in the first eight months of the year. Conversely, imports from China to Germany surged by 8.3% during the same period.
Automotive Sector Faces Supply Chain Headwinds
Volkswagen (VOW) has stated it cannot exclude the possibility that ongoing problems with chip supplier Nexperia could have an effect on its production in the short term. The issue stems from a dispute where the Dutch government seized control of Nexperia, a subsidiary of China's Wingtech, leading to China banning exports of the company's finished products. Nexperia's chips, while not high-end, are widely used in large volumes across the automotive industry, making any disruption critical for manufacturers like Volkswagen, Mercedes-Benz, and Stellantis.
Other Market Movers
JPMorgan has downgraded HP Inc. (HPQ) from Overweight to Neutral, maintaining a price target of $30, citing a tougher backdrop into 2026. The analyst noted that the company is transitioning from favorable conditions, with the Windows 10 replacement cycle concluding in 2026, posing tough comparisons for commercial PC growth.
In central banking news, ECB Vice-President Luis de Guindos is scheduled to speak at the Barcelona Real Assets Meeting 2025.
Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications.